Who Paid My Doc
Barostim Neo System
Device Heart Failure and Hypertension
General payments
$6,662,287
Research payments
$16,658,079
Through program year 2025, $6,662,287 in general payments and $16,658,079 in research payments were reported against Barostim Neo System (Heart Failure and Hypertension).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,836,763 | 17,954 |
| 2025 | Research | $872,302 | 277 |
| 2024 | General | $1,517,991 | 16,025 |
| 2024 | Research | $1,160,453 | 350 |
| 2023 | General | $1,235,117 | 11,518 |
| 2023 | Research | $2,842,004 | 627 |
| 2022 | General | $877,360 | 8,394 |
| 2022 | Research | $2,253,989 | 380 |
| 2021 | General | $606,551 | 3,562 |
| 2021 | Research | $2,236,268 | 347 |
| 2020 | General | $290,310 | 651 |
| 2020 | Research | $2,557,170 | 351 |
| 2019 | General | $298,196 | 372 |
| 2019 | Research | $4,735,893 | 733 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 105 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
58,476 general · 3,065 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.